AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30292578 — intervention group
Group type: COMPARATOR
Intervention: Sensor-augmented pump therapy (Control)
Number of subjects: 86
Study 28939581 — intervention group
Group type: EXPERIMENTAL
Intervention: VZV vaccination (live-attenuated VZVOka vaccine)
Number of subjects: 44
Study 25416522 — intervention group
Group type: EXPERIMENTAL
Intervention: iPad (active distraction)
Number of subjects: 39
Study 25416522 — intervention group
Group type: COMPARATOR
Intervention: AV glasses (passive distraction)
Number of subjects: 39
Study 24146455 — intervention group
Group type: EXPERIMENTAL
Intervention: Cappra(®)
Number of subjects: 63
Study 24146455 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 21685235 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib (1500 mg/d) for three weeks
Number of subjects: 60
Study 21685235 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 21685235 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib
Number of subjects: 60
Study 18085743 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab plus methotrexate (MTX)
Number of subjects: 525
Study 18085743 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX) monotherapy
Number of subjects: 525
Study 16487220 — intervention group
Group type: EXPERIMENTAL
Intervention: TDS-testosterone (50 mg)
Number of subjects: 12
Study 16487220 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgel (1% topical testosterone gel)
Number of subjects: 12
Study 16487220 — intervention group
Group type: COMPARATOR
Intervention: TDS-placebo
Number of subjects: 12
Study 16487220 — intervention group
Group type: EXPERIMENTAL
Intervention: TDS-testosterone and Androgel
Number of subjects: 12
Study 12066421 — intervention group
Group type: EXPERIMENTAL
Intervention: Fictitious medication with varying sample sizes (4, 6, 8, or 40 trials) and contingency (delta P = .20, .40, .60, or .80)
Number of subjects: 30
Study 10321913 — intervention group
Group type: EXPERIMENTAL
Intervention: 17beta-estradiol 50 microg/day
Number of subjects: 292
Study 10321913 — intervention group
Group type: EXPERIMENTAL
Intervention: 17beta-estradiol 75 microg/day
Number of subjects: 292
Study 10321913 — intervention group
Group type: EXPERIMENTAL
Intervention: 17beta-estradiol 100 microg/day
Number of subjects: 292
Study 10321913 — intervention group
Group type: EXPERIMENTAL
Intervention: 17beta-estradiol (all doses)
Number of subjects: 292
Study 10321913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 292
Study 8621845 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (NS), 4 mg inhaled, 4 times daily for 3 months
Number of subjects: 26
Study 8621845 — intervention group
Group type: COMPARATOR
Intervention: Placebo, 4 times daily for 3 months
Number of subjects: 26
Study 1774443 — intervention group
Group type: EXPERIMENTAL
Intervention: Parlodel LAR (long-acting intramuscularly injectable depot preparation of bromocriptine)
Number of subjects: 20
Study 1774443 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1774443 — intervention group
Group type: EXPERIMENTAL
Intervention: Parlodel LAR
Number of subjects: 20
Study 1774443 — intervention group
Group type: EXPERIMENTAL
Intervention: Parlodel LAR and Placebo
Number of subjects: 20
Study 7048890 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose sweetened cakes and ice creams
Number of subjects: 26
Study 7048890 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice creams
Number of subjects: 26
Study 7048890 — intervention group
Group type: COMPARATOR
Intervention: Sucrose sweetened cakes and ice creams
Number of subjects: 26
Study 7048890 — intervention group
Group type: COMPARATOR
Intervention: Cakes
Number of subjects: 26
Study 30239596 — intervention group
Group type: EXPERIMENTAL
Intervention: Panfacial aesthetic treatment
Number of subjects: 2000
Study 28967495 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 36
Study 28967495 — intervention group
Group type: COMPARATOR
Intervention: Placebo (mock LLLT)
Number of subjects: 36
Study 26088885 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam + Phenytoin
Number of subjects: 150
Study 26088885 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam + Valproate
Number of subjects: 150
Study 26088885 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam + Levetiracetam
Number of subjects: 150
Study 26088885 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment (Lorazepam + 1st AED)
Number of subjects: 150
Study 26088885 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment (with addition of 2nd AED)
Number of subjects: 150
Study 26088885 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment (with addition of 3rd AED)
Number of subjects: 150
Study 26088885 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality within 1 month
Number of subjects: 150
Study 26088885 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 150
Study 24862386 — intervention group
Group type: EXPERIMENTAL
Intervention: Goldmann applanation tonometry with silicone hydrogel contact lens
Number of subjects: 28
Study 24862386 — intervention group
Group type: COMPARATOR
Intervention: Goldmann applanation tonometry without silicone hydrogel contact lens
Number of subjects: 28
Study 24862386 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of both measurements
Number of subjects: 28
Study 24862386 — intervention group
Group type: EXPERIMENTAL
Intervention: Bland-Altman analysis
Number of subjects: 28
Study 22472294 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic anticoagulation
Number of subjects: 0
Study 22472294 — intervention group
Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 0
Study 19717942 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent ultrasound (group 1, n=20)
Number of subjects: 36
Study 19717942 — intervention group
Group type: COMPARATOR
Intervention: Placebo ultrasound (group 2, n=16)
Number of subjects: 36
Study 17689931 — intervention group
Group type: EXPERIMENTAL
Intervention: Effective rTMS (10 Hz, 110% of motor threshold intensity, 15 sessions)
Number of subjects: 22
Study 17689931 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS (ineffective treatment)
Number of subjects: 22
Study 15077097 — intervention group
Group type: EXPERIMENTAL
Intervention: Monteplase (1,600,000 IU IV), n = 19
Number of subjects: 39
Study 15077097 — intervention group
Group type: COMPARATOR
Intervention: Nontreatment group, n = 20
Number of subjects: 39
Study 11354297 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheohemapheresis
Number of subjects: 0
Study 11354297 — intervention group
Group type: COMPARATOR
Intervention: Conventional hemorheotherapy
Number of subjects: 0
Study 9146770 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole once daily + 1000 mg amoxycillin b.d. (days 5-14)
Number of subjects: 163
Study 9146770 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole b.d. + 1000 mg amoxycillin b.d. (days 5-14)
Number of subjects: 163
Study 9146770 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg omeprazole b.d. + 1000 mg amoxycillin b.d. (days 5-14)
Number of subjects: 163
Study 9146770 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg omeprazole b.d. + 1000 mg amoxycillin b.d. (days 5-14)
Number of subjects: 163
Study 7711430 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interleukin-2 and interferon-alpha 2b (rIL-2 and IFN-alpha 2b) administered subcutaneously for 6 weeks (3 treatment cycles, each with 3 weeks of administration)
Number of subjects: 30
Study 7711430 — intervention group
Group type: COMPARATOR
Intervention: Dacarbazine in addition to rIL-2 and IFN-alpha 2b
Number of subjects: 30
Study 3330985 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (50 mg, twice daily; n = 7)
Number of subjects: 14
Study 3330985 — intervention group
Group type: COMPARATOR
Intervention: Propranolol or alphamethyldopa (n = 7)
Number of subjects: 14
Study 31814488 — intervention group
Group type: COMPARATOR
Intervention: 30mg MDMA
Number of subjects: 13
Study 31814488 — intervention group
Group type: COMPARATOR
Intervention: 70mg MDMA
Number of subjects: 13
Study 29186562 — intervention group
Group type: EXPERIMENTAL
Intervention: REACH for Control (RFC) plus standard medical care
Number of subjects: 50
Study 29186562 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC) only
Number of subjects: 50
Study 28303642 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen matrix seal (CMS)
Number of subjects: 28
Study 28303642 — intervention group
Group type: COMPARATOR
Intervention: Collagen sponge (CS)
Number of subjects: 28
Study 25960401 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of stay (LOS) ≥14 days
Number of subjects: 4020
Study 25960401 — intervention group
Group type: COMPARATOR
Intervention: Length of stay (LOS) ≤3 days
Number of subjects: 4020
Study 24048467 — intervention group
Group type: EXPERIMENTAL
Intervention: HAS-BLED score
Number of subjects: 2293
Study 24048467 — intervention group
Group type: COMPARATOR
Intervention: CHADS2 score
Number of subjects: 2293
Study 24048467 — intervention group
Group type: COMPARATOR
Intervention: CHA2DS2-VASc score
Number of subjects: 2293
Study 21161185 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of hydrocortisone
Number of subjects: 113
Study 21161185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study 19217154 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab (90 mg or 63 mg) every week for 4 weeks (weeks 0-3)
Number of subjects: 146
Study 19217154 — intervention group
Group type: COMPARATOR
Intervention: Ustekinumab (63 mg) at weeks 12 and 16
Number of subjects: 146
Study 19217154 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab (90 mg or 63 mg)
Number of subjects: 146
Study 19217154 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study 19217154 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Number of subjects: 146
Study 16708768 — intervention group
Group type: EXPERIMENTAL
Intervention: Gynostemma pentaphyllum (GP) extraction 80 mL for 4 months after 2 months of controlled diet
Number of subjects: 56
Study 16708768 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsule for 4 months after 2 months of controlled diet
Number of subjects: 56
Study 16708768 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups followed a controlled diet for 2 months
Number of subjects: 56
Study 16708768 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups measured for uric acid levels from month 2 to month 6
Number of subjects: 56
Study 15636412 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent treatment intervention (MTI)
Number of subjects: 42
Study 15636412 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 42
Study 11206682 — intervention group
Group type: EXPERIMENTAL
Intervention: Benidipine (6 months)
Number of subjects: 43
Study 11206682 — intervention group
Group type: COMPARATOR
Intervention: Placebo (6 weeks)
Number of subjects: 43
Study 11206682 — intervention group
Group type: EXPERIMENTAL
Intervention: Benidipine (6 weeks)
Number of subjects: 43
Study 11206682 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (6 weeks)
Number of subjects: 43
Study 9028542 — intervention group
Group type: EXPERIMENTAL
Intervention: Premenopausal females (mean age for menopause - 2 SD to + 2 SD, 43-57 years)
Number of subjects: 429
Study 9028542 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmenopausal females (mean age for menopause - 2 SD to + 2 SD, 43-57 years)
Number of subjects: 429
Study 9028542 — intervention group
Group type: EXPERIMENTAL
Intervention: Spine BMD in premenopausal females
Number of subjects: 429
Study 9028542 — intervention group
Group type: EXPERIMENTAL
Intervention: Spine BMD in postmenopausal females
Number of subjects: 429
Study 9028542 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral neck BMD in premenopausal females
Number of subjects: 429
Study 9028542 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral neck BMD in postmenopausal females
Number of subjects: 429
Study 9028542 — intervention group
Group type: EXPERIMENTAL
Intervention: Trochanter BMD in premenopausal females
Number of subjects: 429
Study 9028542 — intervention group
Group type: EXPERIMENTAL
Intervention: Trochanter BMD in postmenopausal females
Number of subjects: 429
Study 9028542 — intervention group
Group type: EXPERIMENTAL
Intervention: Ward's triangle BMD in premenopausal females
Number of subjects: 429
Study 9028542 — intervention group
Group type: EXPERIMENTAL
Intervention: Ward's triangle BMD in postmenopausal females
Number of subjects: 429
Study 8280541 — intervention group
Group type: EXPERIMENTAL
Intervention: Cricoid pressure
Number of subjects: 100
Study 8280541 — intervention group
Group type: COMPARATOR
Intervention: No cricoid pressure
Number of subjects: 100
Study 3566867 — intervention group
Group type: EXPERIMENTAL
Intervention: Fe (III)‐hydroxide‐polymaltose complex
Number of subjects: 16
Study 3566867 — intervention group
Group type: EXPERIMENTAL
Intervention: Fe (II)‐ascorbate
Number of subjects: 16
Study 3566867 — intervention group
Group type: EXPERIMENTAL
Intervention: Fe (III)‐hydroxide‐polymaltose complex with test meal
Number of subjects: 16
Study 3566867 — intervention group
Group type: EXPERIMENTAL
Intervention: Fe (III)‐complex
Number of subjects: 16
Study 3566867 — intervention group
Group type: EXPERIMENTAL
Intervention: Fe (II)‐sulphate
Number of subjects: 16
Study 3566867 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 16
Study 2661734 — intervention group
Group type: EXPERIMENTAL
Intervention: CMFPT (cyclophosphamide, methotrexate, fluorouracil, prednisone plus tamoxifen)
Number of subjects: 265
Study 2661734 — intervention group
Group type: EXPERIMENTAL
Intervention: CMFP (cyclophosphamide, methotrexate, fluorouracil, prednisone)
Number of subjects: 265
Study 2661734 — intervention group
Group type: EXPERIMENTAL
Intervention: CMFP (+/‐ T)
Number of subjects: 265
Study 2661734 — intervention group
Group type: EXPERIMENTAL
Intervention: CMFP
Number of subjects: 265
Study 2661734 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 265
Study 2661734 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant treatment
Number of subjects: 265
Study 30298463 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow temporal window (TW) for simultaneous perception as measured by a temporal order judgement task
Number of subjects: 0
Study 30298463 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced ability to engage in multisensory integration during the sound-induced flash illusion task
Number of subjects: 0
Study 30298463 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow TW
Number of subjects: 0
Study 31368422 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Ca fat-free milk (HC)
Number of subjects: 14
Study 31368422 — intervention group
Group type: COMPARATOR
Intervention: Low-Ca control diet (LC)
Number of subjects: 14
Study 27830294 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutant L205A
Number of subjects: 0
Study 27830294 — intervention group
Group type: COMPARATOR
Intervention: Wild-type ChKRED20
Number of subjects: 0
Study 26002690 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 270
Study 26002690 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 270
Study 23337646 — intervention group
Group type: EXPERIMENTAL
Intervention: Alginate dressing and polyurethane film
Number of subjects: 30
Study 23337646 — intervention group
Group type: COMPARATOR
Intervention: Nonadherent paraffin gauze
Number of subjects: 30
Study 21708003 — intervention group
Group type: EXPERIMENTAL
Intervention: My PKU web page with access to blood Phe values
Number of subjects: 38
Study 21708003 — intervention group
Group type: COMPARATOR
Intervention: Usual procedure (phone call or e-mail by a dietician)
Number of subjects: 38
Study 19621425 — intervention group
Group type: EXPERIMENTAL
Intervention: GST‐M1 null genotype
Number of subjects: 36
Study 19621425 — intervention group
Group type: EXPERIMENTAL
Intervention: GST‐M1 normal genotype
Number of subjects: 36
Study 19621425 — intervention group
Group type: EXPERIMENTAL
Intervention: GST‐M1 genotype
Number of subjects: 36
Study 19621425 — intervention group
Group type: EXPERIMENTAL
Intervention: ABCB1 C3435T genotype
Number of subjects: 36
Study 16671836 — intervention group
Group type: EXPERIMENTAL
Intervention: Musical story
Number of subjects: 64
Study 16671836 — intervention group
Group type: EXPERIMENTAL
Intervention: Spoken story
Number of subjects: 64
Study 16671836 — intervention group
Group type: COMPARATOR
Intervention: Standard care/control
Number of subjects: 64
Study 15544589 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-36
Number of subjects: 224
Study 15544589 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhinitis QOL Questionnaire (RQLQ)
Number of subjects: 224
Study 11422765 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral iron administration (iron dextran 100 mg at ten consecutive dialysis sessions)
Number of subjects: 208
Study 11422765 — intervention group
Group type: COMPARATOR
Intervention: No parenteral iron administration
Number of subjects: 208
Study 9404740 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure ventilation (NPV) by a poncho-wrap ventilator
Number of subjects: 27
Study 9404740 — intervention group
Group type: COMPARATOR
Intervention: Control group (spontaneous assisted ventilation)
Number of subjects: 27
Study 8501147 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 IU GH (iv infusion)
Number of subjects: 25
Study 8501147 — intervention group
Group type: COMPARATOR
Intervention: 5 IU GH (im bolus injection)
Number of subjects: 25
Study 8501147 — intervention group
Group type: COMPARATOR
Intervention: 48 IU GH (iv infusion)
Number of subjects: 25
Study 8501147 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 micrograms/h GHRH (iv infusion)
Number of subjects: 25
Study 8501147 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 3125077 — intervention group
Group type: EXPERIMENTAL
Intervention: Enterococcus lactic acid bacteria strain SF68 (two capsules three times daily)
Number of subjects: 40
Study 3125077 — intervention group
Group type: COMPARATOR
Intervention: Lactulose (30 ml four times daily)
Number of subjects: 40
Study 29525739 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation
Number of subjects: 111
Study 29525739 — intervention group
Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 111
Study 26717867 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT) pre-operatively for CAS
Number of subjects: 77
Study 26717867 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT) post-operatively for CAS
Number of subjects: 77
Study 26717867 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT) pre-operatively for CEA
Number of subjects: 77
Study 26717867 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT) post-operatively for CEA
Number of subjects: 77
Study 26717867 — intervention group
Group type: EXPERIMENTAL
Intervention: Mono antiplatelet therapy (MAPT) post-procedural
Number of subjects: 77
Study 26717867 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing for antiplatelet therapy resistance
Number of subjects: 77
Study 24515619 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg
Number of subjects: 66
Study 22810570 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar substitute products
Number of subjects: 60
Study 22810570 — intervention group
Group type: COMPARATOR
Intervention: Conventional sugar
Number of subjects: 60
Study 20919760 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment Advocacy Program (TAP)
Number of subjects: 313
Study 20919760 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 313
Study 17498071 — intervention group
Group type: EXPERIMENTAL
Intervention: Reformulated BeneFix
Number of subjects: 17
Study 16313478 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg 17beta-oestradiol plus 1 mg DRSP
Number of subjects: 240
Study 16313478 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg 17beta-oestradiol plus 2 mg DRSP
Number of subjects: 240
Study 16313478 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg 17beta-oestradiol plus 3 mg DRSP
Number of subjects: 240
Study 16313478 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 12484506 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitor plus spironolactone (25 mg) for 60 weeks
Number of subjects: 20
Study 12484506 — intervention group
Group type: COMPARATOR
Intervention: ACE inhibitor alone for 60 weeks
Number of subjects: 20
Study 10716206 — intervention group
Group type: EXPERIMENTAL
Intervention: Colour flicker
Number of subjects: 0
Study 10716206 — intervention group
Group type: EXPERIMENTAL
Intervention: Luminance flicker
Number of subjects: 0
Study 10716206 — intervention group
Group type: EXPERIMENTAL
Intervention: Coloured objects
Number of subjects: 0
Study 10716206 — intervention group
Group type: COMPARATOR
Intervention: Grey-scaled objects
Number of subjects: 0
Study 10716206 — intervention group
Group type: COMPARATOR
Intervention: Coloured flicker
Number of subjects: 0
Study 10716206 — intervention group
Group type: COMPARATOR
Intervention: Chromatic flicker
Number of subjects: 0
Study 7590617 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 1 mg given at 11:00 p.m. on on-call night
Number of subjects: 42
Study 7590617 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone 1 mg given at 11:00 p.m. on control night
Number of subjects: 42
Study 7590617 — intervention group
Group type: EXPERIMENTAL
Intervention: On-call night
Number of subjects: 42
Study 7590617 — intervention group
Group type: COMPARATOR
Intervention: Control night
Number of subjects: 42
Study 2075246 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemeprost (16,16 dimethyl-PGE1-methyl ester) pessaries
Number of subjects: 0
Study 2075246 — intervention group
Group type: COMPARATOR
Intervention: Intra-amniotic PGF2 alpha combined with hypertonic saline, intravenous oxytocin, and a hygroscopic cervical dilator (Dilapan)
Number of subjects: 0
Study 6115654 — intervention group
Group type: EXPERIMENTAL
Intervention: bunitrolol
Number of subjects: 20
Study 6115654 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 30407895 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 23
Study 29871023 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive homeopathy
Number of subjects: 612